Contrasting Sinopharm Group (OTCMKTS:SHTDY) and McKesson (NYSE:MCK)
Sinopharm Group (OTCMKTS:SHTDY – Get Free Report) and McKesson (NYSE:MCK – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership. Earnings & Valuation This table compares Sinopharm Group and […] Sinopharm Group (OTCMKTS) and McKesson (NYSE:MCK) are both medical companies, but which is the superior investment? This is based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, and institutional ownership. McKesson has higher revenue and earnings than Sinopharm group, indicating it is the more affordable of the two stocks. This is also a breakdown of recent ratings for Sinophar Group and McKesson, which have a consensus price target of $457.54 suggesting a potential upside of 1.04%.
Опубликовано : 2 года назад от Defense World Staff в Finance
Sinopharm Group (OTCMKTS:SHTDY – Get Free Report) and McKesson (NYSE:MCK – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends and institutional ownership.
This table compares Sinopharm Group and McKesson’s revenue, earnings per share and valuation.
McKesson has higher revenue and earnings than Sinopharm Group. Sinopharm Group is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent ratings for Sinopharm Group and McKesson, as reported by MarketBeat.
McKesson has a consensus price target of $457.54, suggesting a potential upside of 1.04%. Given McKesson’s higher probable upside, analysts clearly believe McKesson is more favorable than Sinopharm Group.
This table compares Sinopharm Group and McKesson’s net margins, return on equity and return on assets.
McKesson beats Sinopharm Group on 9 of the 10 factors compared between the two stocks.
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients by working across healthcare; connects patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to deliver innovative solutions to help people get the medicine needed to live healthier lives; and provides prescription price transparency, benefit insight, dispensing support, third-party logistics, and wholesale distribution support services. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. The International segment offers distribution and services to wholesale, institutional, and retail customers in Europe and Canada. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
Темы: Markets, NYSE